Addict Behav:止痛药依赖让海洛因成瘾问题更加复杂

2015-08-20 佚名 生物谷

 毒品(鸦片)一直是很多社会黑暗现象的根源。在大多数地方,只有很少的海洛因流通在社会上。但是,在很多美国年轻白人中出现了一种越来越明显的趋势,那就是在吸食海洛因的同时,还滥用处方止痛药。这种海诺因-止痛药的组合似乎很有吸引力,吸引着很多不吸食海洛因的人群开始尝试这个组合。南佛罗里达州大学的助理教授Khary K. Rigg和宾夕法尼亚州立大学的助理教授Shannon M. Monnat

毒品(鸦片)一直是很多社会黑暗现象的根源。在大多数地方,只有很少的海洛因流通在社会上。但是,在很多美国年轻白人中出现了一种越来越明显的趋势,那就是在吸食海洛因的同时,还滥用处方止痛药。这种海诺因-止痛药的组合似乎很有吸引力,吸引着很多不吸食海洛因的人群开始尝试这个组合。南佛罗里达州大学的助理教授Khary K. Rigg和宾夕法尼亚州立大学的助理教授Shannon M. Monnat对此趋势进行了研究,相关工作发表在Addictive Behaviors

他们发现,近年来,越来越多的年轻白人开始尝试海洛因和处方止痛药一起服用,而且这个现象似乎有愈演愈烈的趋势。这种现实可能是二三十年前人们对止痛药依赖的多米诺骨牌效应。在1980年代和1990年代,美国一些地区出现了处方止痛药的滥用,导致人们对于止痛药存在药物依赖。后来,止痛药的滥用受到了很多限制,所以很多有止痛药物依赖的人群开始转向更便宜、容易获得的海洛因。这其中,就有一些人开始尝试同时服用处方止痛药和吸食海洛因。当然也有一部分人坚持只服用止痛药。但是同时服用止痛药和吸食海洛因的人群增长速度更快。

根据美国国家药品使用与健康状况调查(2010-2013)的数据,三种人群(止痛药成瘾、止痛药-海洛因成瘾、海洛因成瘾)的群体数量不一,其中止痛药成瘾人群数量最大,止痛药-海洛因成瘾则其次。根据这个研究,最新的数据显示,美国止痛药-海洛因成瘾人群的数量大有快速扩大的趋势。这对于更多的人们带来了新的健康威胁,针对这种现象治疗的专业医护人员培养也需要得到重视。

一般地,吸食海洛因人群的社会学特征是,这些人多半是居住在城区的贫困黑人。但是似乎有新的趋势发现,越来越多的白人青年开始止痛药-海洛因成瘾,而且这些白人多是有正当职业并居住在乡村或者小城镇。相对来说,只有止痛药成瘾的人群相对于海洛因成瘾、止痛药-海洛因成瘾的人群有相对更好的生理和精神状态。然而,随着海洛因(以及止痛药-海洛因)成瘾人群的扩大,更多人把自己暴露在了HIV和性相关的疾病风险环境中。而我们所能做的是,珍爱生命,远离毒品

原始出处:

Rigg KK, Monnat SM.Comparing Characteristics of Prescription Painkiller Misusers and Heroin Users in the United States.Addict Behav. 2015 Jul 26;51:106-112. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2016-09-15 1e10c84am36(暂无匿称)

    文章不错,值得拜读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2016-06-22 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]
    2015-08-22 qjddjq
  7. [GetPortalCommentsPageByObjectIdResponse(id=127170, encodeId=087612e170be, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:40:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858621, encodeId=61cf1858621d6, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Jun 22 23:33:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947830, encodeId=e57d194e8307b, content=<a href='/topic/show?id=e54d8483db' target=_blank style='color:#2F92EE;'>#HAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8483, encryptionId=e54d8483db, topicName=HAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 17 17:33:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289947, encodeId=fd94128994e99, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405496, encodeId=8f8b140549602, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521848, encodeId=1e6f1521848f6, content=<a href='/topic/show?id=f83866137f' target=_blank style='color:#2F92EE;'>#EHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6613, encryptionId=f83866137f, topicName=EHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937d11405368, createdName=qjddjq, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523494, encodeId=3897152349427, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Sat Aug 22 01:33:00 CST 2015, time=2015-08-22, status=1, ipAttribution=)]

相关资讯

FDA敦促怀孕期间谨慎使用止痛药

在今天发布的一份药品安全通信中,美国食品药品监督管理局(FDA)表示,他们已经意识到对最近报告的“质疑”,包括怀孕期间使用处方药和非处方止疼药(OTC)的安全性,但缺乏足够的研究改变目前的用药现状。 怀孕期间使用处方药和非处方药的益处和风险需要仔细权衡,美国食品药品监督管理局提醒医疗服务提供者应多沟通。 美国食品药品监督管理局评估发表以下研究: •处方的非甾体类抗炎药物(如布洛芬、萘普生、双

痛药领域迎转机?FDA批准礼来NGF止痛药物项目重启 !

止痛药物曾经因为其广泛的使用领域和巨大的市场前景而获得众多生物医药巨头的追捧。然而随着药物滥用及各种副作用的发现,FDA对这种药物的研发工作由大力支持变为了谨慎对待。对这一转变,辉瑞公司和礼来公司可谓心有戚戚。 不过,最近FDA在审阅了两家公司提交的关于其神经生长因子(NGF)类止痛药物tanezumab先期实验的研究数据,终于打消了对这种药物安全性的疑虑,批准其继续进行中断数年之久的临

J Invest Dermatol:常见止痛药可助于预防某些皮肤癌

普通止痛药包括布洛芬,可能会略降低患上皮肤癌的风险。研究人员回顾9项以前的研究后得出结论,使用布洛芬和萘普生,鳞状细胞皮肤癌的风险15%降低。鳞状细胞皮肤癌通常是由太阳暴晒引起的。 这些止痛药有潜力成为皮肤癌预防战略的一部分。但研究人员都没有准备好推荐这些或其他非甾体抗炎药(NSAIDs)以防止皮肤癌。Joshua Zeichner博士表示:不要依靠服用阿司匹林或其他非甾体类抗炎药,以保护你的皮

Zogenix加速止痛药Zohydro研发审批进程

Zogenix公司最近宣布公司对于改进其强效止痛药Zohydro已经取得了重要进展。据了解,此次改进主要是为了满足FDA对其要求的防止Zohydro被滥用。公司表示计划在今年十月份向FDA提交胶囊型Zohydro,这种剂型的Zohydro将更难以被成瘾者滥用。公司计划于明年使Zohydro正式上市。然而,这对于Zogenix公司来说还不是高兴的时候。 今年来世界各大制药巨头纷纷进军非成瘾类止

Endo、BDSI止痛药物三期临床研究获得良好结果即将申报FDA

著名止痛药生产者Endo生物医药公司最近宣布公司开发的新型止痛药BEMA 叔丁啡临床三期研究达到了预期目标,这也为Endo公司向FDA提交上市申请扫清了障碍。BEMA(BioErodable MucoAdhesive)是一种基于BioDelivery Sciences International公司的载药系统开发而成的新型止痛药。临床研究显示,患者使用这种药物15分钟内即可明显抑制病痛。BEM

JAMA Pediatr:儿童止痛药——一次处方用药几何?

阿片类药物滥用率增高、不良反应和阿片类药物导致的死亡增多都是和处方模式直接相关的,这表明医生用于缓解病人病痛的努力已经造成了公共卫生危机。儿童和青少年尤其容易遭受处方阿片类药物的过剂量使用和滥用。据估计,由阿片类药物非故意导致的儿童和青少年死亡分别为每100000人中0.1和3.7人。半数滥用处方类阿片药物的青少年是从他们先前的处方、朋友或家人处得到阿片类药物。考虑到日益增长的公共卫生关注点,美国